Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Erlangen-Nürnberg Medical School
M.D. Anderson Cancer Center
Jazz Pharmaceuticals
Dana-Farber Cancer Institute
AstraZeneca
Mayo Clinic
Baylor College of Medicine
Avacta Life Sciences Ltd
Brigham and Women's Hospital
University of Nebraska
NRG Oncology
Big Ten Cancer Research Consortium
VM Oncology, LLC
Vanderbilt University Medical Center
LigaChem Biosciences, Inc.
University of Colorado, Denver
Peking Union Medical College
Abramson Cancer Center at Penn Medicine
Huashan Hospital
Jonsson Comprehensive Cancer Center
Dana-Farber Cancer Institute
National University Hospital, Singapore
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano